Stephanie Reuter
stephanie.reuter@hartmann.info
+49 173 3453885
The increase in the earnings forecast comes despite unchanged market challenges, such as reduced market demand and high burdens from additional material costs, as well as increases in personnel costs.
“The improvement in earnings is the result of structural cost reductions and the market launch of new products that offer our customers measurable benefits. This also increases our competitive strength in a market environment that remains difficult,” says Britta Fünfstück, CEO of the HARTMANN GROUP.
The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.
To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.